Dr. Rohit Varma is an internationally renowned scientist and physician specializing in the field of retinal and visual development in children. He has published more than 350 scientific articles, reviews, book chapters, and abstracts, and served as the principal investigator on research grants from the National Institutes of Health totaling at least $23 million. He also serves on one of the five component boards of the National Institutes of Health's Clinical Trials Group, which is one of 10 institutes within the NIH.

1. Dr.RohitVarma’sJourney
From a Student to Founding Director

2. Contoso
Pharmaceuticals
FoundingDirectorofSCEI
–Dr.RohitVarma
Ophthalmologist and Physician-
Scientist, Founder of Southern
California Eye Institute (SCEI)
page 2

3. Contoso
Pharmaceuticals
EarlyLifeinIndia
page 3
• Going back to his past, starting from his childhood
days, Dr. Varma born and brought up in middle class
family with very traditional ways of living.
• School- In school days he was very shy kid and one of
the most favorite kid of his teacher, among other
students in class. After 10th, he had planned to opt for
medical science as major subjects and after clearly 10th
with flying colours, he got admission in one of the best
hr. secondary school of the region through merit- based
scholarship.
• College- After completion of 10+2 he had appeared for
the competitive exams based for the admission in
prestigious medical colleges of country, and as
expected he clearly the entrance exam and got merit
ranking to get into MBBS program in one of the best
medical colleges of Delhi university.

4. Contoso
Pharmaceuticals
page 4
• During his graduate study days, he has made his
mind to opt for the further studies in the field of
vision science and related field of
ophthalmology and pursue his further career in
overseas education programs.
• After getting the M.D degree Dr. Varma went for
M.P.H from US.

5. Contoso
Pharmaceuticals
StudyinginUSA
page 5
• After completing graduation Varma came USA in 1987.
Then he applied for M.P.H in Johns Hopkins School of
Public Health in filed of Epidemiology.
• After completing his M.P.H from Johns Hopkins School
of Public Health . He further applied for Postdoc at Wills
Eye Hospital, Thomas Jefferson University in the field
of glaucoma.
• In 1989, after completing this Postdoc from Wills Eye
Hospital, Thomas Jefferson University . He did an
internship at Union Memorial Hospital, University of
Maryland. In the field of Internal Medicine.
• He completed his resident in ophthalmology from
Wilmer Eye Institute, Johns Hopkins School of
Medicine in the year 1993.
• After that, he completed his fellowship from Keck
School of Medicine of University of Southern California
in the filed of glaucoma in the year 1994.

6. Contoso
Pharmaceuticals
WorkHistory-Dr.Rohit Varma
page 6
• This first job was as a Clinical Instructor in the
department of Ophthalmology at the Keck
School of Medicine of University of Southern
California.
• Then he was promoted to assistant professor in
the same department.
• After that, he was again promoted to Associate
Professor in the year 1999.
• After that he became the professor in 2005 for
the department of Ophthalmology and
Preventive Medicine.
• In the year 2012, he got the Chair of Ocular
Research in the department of Ophthalmology &
Visual Sciences. For the Illinois Eye and Ear
Infirmary , College of Medicine, University of
Illinois at Chicago

7. Contoso
Pharmaceuticals
page 7
• In the year 2016, May S. and John Hooval Dean’s Chair in Medicine in the Keck School of Medicine at the
University of Southern California.
• After that he got his last promotion in the year 2014 as the Grace and Emery Beardsley Chair and
Professor in the department of Ophthalmology and Preventive Medicine at the Keck School of Medicine
of University of Southern California.
• Most recently in the year 2018, he became the President and Chief Executive Officer in the department of
CHA Medical and Surgical Group, PC at the CHA Hollywood Presbyterian Medical Center.
• Also, in 2018 he became the Founding Director of Southern California Eye Institute (SCEI) at CHA
Hollywood Presbyterian Medical Center.

8. Contoso
Pharmaceuticals
Each patient receives personalized and
compassionate treatment at every
point. We use state-of-of-the-the-the-
the-the-art technology methods and
innovative imaging techniques that help
us craft personalized care plans for our
patients. Additionally, our clinician
scientists and researchers are working
on enhancing the bioelectronics, stem
cell and regenerative therapies, and life-
Enlightened leadership by Dr. Kwang Yul
Cha, Dr. Jae-Hoon Song and Mr. Allen of
CHA Hollywood Presbyterian Health
Center, the new facility was activated.
We're excited to serve patients and to
meet their most pressing needs,
whether it be restoring their sight or
creating hope.
SCEI–(SOUTHERN
CALIFORNIAEYEINSTITUTE)
This is an age of miracles.Thanks to
advancements on every front—from
wireless to innovative new devices our
institute is making bold strides on our
pledge to ending blindness. Our work is
both evolutionary—building on findings
that have come before—and
revolutionary—making quantum strides
that spark groundbreaking solutions.
The result: new growth, new
opportunities and new hope.
page 8

9. Contoso
Pharmaceuticals
HPMC–(HollywoodPresbyterianMedicalCenter)
page 9
• Rohit Varma, MD, MPH, has been Chief Medical
Officer of CHA Hollywood Presbyterian Medical
Center, a nationally recognized acute care
facility offering compassionate service to
Hollywood and its surrounding communities
since 1924. He is also the founding director of
the Southern California Eye Institute (SCEI)
located inside CHA's Hollywood Presbyterian
Medical Center.
• Dr. Rohit Varma, a successful physician-scientist
and board-certified ophthalmologist, is known
worldwide as a pioneering pioneer in glaucoma
and epidemiology of eye diseases. He is an
authority on changes in the optic nerve in
glaucoma and is also researching new imaging
methods for early detection of glaucoma
damage to the optic nerve.

10. Contoso
Pharmaceuticals
page 10
•CHA Hollywood Presbyterian Hospital has
provided for the city of L.A.A. and its
inhabitants since the beginning of the 20th
century. In addition to today's four-four-434-
bed intensive care hospital, there are 89 skilled
nursing beds.
•More than 500 doctors and 69 different
specialties are at the hospital. To everyone who
comes in here, we treat them with kindness
and respect It is part of CHA Health Systems, a
diverse healthcare entity that has 25 hospitals
and 3 along with 30 research and educational
facilities, and 14 bio/pharmaceutical/health
care facilities. for more information, visit
http://https://rohitvarmamd.wordpress.com/
SOURCE-asbarez.com

11. Contoso
Pharmaceuticals
CHA HOLLYWOOD PRESBYTERIAN HOSPITAL
page 11
SOURCE-healthleadersmedia.com

12. Contoso
Pharmaceuticals
RESEARCH’SCONDUCTEDBYDR.ROHITVARMA
• Population Health
• Big Data & Artificial Intelligence
• NovelTreatments
page 12
SOURCE- nature.com

13. Contoso
Pharmaceuticals
RESEARCHONPOPULATIONHEALTH
• Notable epidemiologic studies are being conducted by SCEI Director Dr. Rohit Varma, MD, MPH .Many
cases of visual impairment can be helped with routine eye checks and prompt action, and campaigns to
cure eye diseases . With support from the NIH and other organizations, Varma and his research teams
completed the largest-ever studies on Latino, black, Asian American, and mixed-race children in the U.S.
• These population-based studies are:
• Los Angeles Latino Eye Study (LALES)
• Chinese American Eye Study (CHES)
• African American Eye Disease Study (AFEDS)
• Multi-Ethnic Pediatric Eye Disease Study (MEPEDS)
• The results are changing national and global policies regarding eye health.
• Over the next three-and-and-half decades, it is predicted that the incidence of blindness and visual
impairment in the US will more than double.
• About 20% of the population of the U.S. will be affected by age-related macular degeneration,
glaucoma, and 30% by diabetes-related retinopathy, by the year 2050.
page 13

14. Contoso
Pharmaceuticals
• according to SCEI, particularly
• over 13.4.2 million adults and older will have refractive
error-correctable scotoma in 2018
• more than 2.4 million 40+ year-olds will be blind and 6.95
million+ will be visually impaired by the year 2050 versus
about
• the women and minority groups bear the greatest
burden
• "Otherwise, long-term academic and social
accomplishments would be negatively impacted by
permanent short-term vision problems early on the
development of childhood," Varma noted This is a health
care imperative.
page 14

15. Contoso
Pharmaceuticals
BIGDATA & ARTIFICALINTELLIGENCE
• Artificial intelligence is now revolutionizing daily eye surgery When artificial intelligence recognizes
patterns or signs of illness, it becomes a diagnostic. diabetic retinopathy, age-related macular
degeneration, macular degeneration, and other eye disorders are now able to be detected by AI.
• At SCEI, we use massive datasets and artificial intelligence to enhance the diagnosis and treatment of
eye conditions Our priority is to make the more advanced care choice available to more patients.
• SCEI Director Rohit Varma, MPH, shared four important insights on artificial intelligence in
Ophthalmology.
• 1) AI is improving It may deliver a higher degree of objectivity and level of accuracy in medical imaging
diagnosis than many human physicians.Widespread use of Big Data is here to bear this opportunity out.
• 2) AI is working with healthcare The new AI offers a well-reasoned explanation for its diagnosis and refers
to a specific element of the scan which yielded the results.This is a big move forward.
• 3) AI shortens time. According to observers, reports indicate that AI can complete non-repetitive tasks in
seconds, rather than hours. Finally, 3D models can be generated from two-dimensional images of eye
tumors as well.
• 4) Affordability will increase access. patients in far-flung locations will be able to use telemedicine to
provide eye exams and consultationsThe data can be sent to a computer for processing.
page 15

16. Contoso
Pharmaceuticals
• Deep learning and retinopathy
• In 2018, Varma ran a study on a deep learning model (DLS)
for detecting eye diseases.
• Identifying referable and age-threatened macular
degeneration in mixed ethnicity groups with diabetic
retinopathy
• The challenge: DL systems had some success in the past ,
but was tested using datasets that consisted entirely of
white populations To truly comprehend the DLS benefits, it
was tested on racial and ethnic groups with different fundi
(the fundus is the interior surface of the eye).
• The Process was learned to detect eye diseases from retinal
scans: They used data from ongoing multiethnic research
conducted in Singapore, as well as 10 additional sets of 10
different other countries with diverse populations.
• The findings have a rating consistency of 90.5 and 91.6%,
respectively, for vision-threatening DR; also, age-related
macular degradation has a rating consistency of 93.2%.
• The Conclusion: Diabetic retinopathy and associated eye
disorders are characteristic.
• Further study is needed to examine the effectiveness of
DLS in healthcare settings. page 16

17. Contoso
Pharmaceuticals
NOVELTREATMENTS
• As fluid builds up in the front part of the eye, putting pressure on the optic nerve, glaucoma may result in
blindness. maintaining normal intraocular pressure (IOP) is key to the best for long-term vision.
• Treatment of intraocular pressure also necessitates tractotomy — the implantation of a flexible drainage
tube — in the eye.
• It turns out that our researchers have created an interesting solution: a stent that is just as thick as a
human hair and made up of collagen-derived gelatin, to replace the hard substance used in current
stents. XEN has been deemed to be suitable for use in humans by the U.S. Food and Drug Administration
(FDA).
• The Xen Gel Stent is an important component of care for patients who have had previous eye surgery not
be of any help in lowering their IOP. It is of benefit to those who don't respond to the full tolerable
medical treatment for open-angle glaucoma.
• Among the several clinical trials done by Allergan to gain FDA approval of the device was the one headed
by SCEI director RohitVarma, M.D., M.P.H. In the year after the surgery,Varma found eye pressure and
prescribing of certain drugs for his patients was reduced by 44% and 65%, respectively. page 17

18. Contoso
Pharmaceuticals
• Among the several clinical trials done by Allergan to
gain FDA approval of the device was the one headed by
SCEI director Rohit Varma, M.D., M.P.H. In the year
after the surgery, Varma found eye pressure and
prescribing of certain drugs for his patients was reduced
by 44% and 65%, respectively.
• XEN gel implant promises a new horizons for glaucoma
ice patients, he said
• To allow for fluid to continue to flow into the anterior
chamber of the eye, the system can be safely injected. If
inserted, the implant takes effect almost immediately.
page 18

19. Contoso
Pharmaceuticals
DIRECTORS ATSCEI
Dr. RohitVarma
Founding Director
Advanced Medical and Surgical
Glaucoma Management, Minimally
Invasive Glaucoma Surgery
Victoria Lindqvist
Associate Medical Director
Advanced Medical and Surgical
Glaucoma Management, Minimally
Invasive Glaucoma Surgery, Anterior
Segment Disease, Comprehensive
Ophthalmology
Angelica Astrom
Director of Ambulatory Surgery
All-Laser Cataract Surgery, Refractive
Surgery, Comprehensive
Ophthalmology
page 19

20. Contoso
Pharmaceuticals
DOCTORS ATSCEI
Dr. Alena
Reznik
Associate Medical
Director
Dr. Jacob
Reznik
Director of
Ambulatory Surgery
Dr. Ora
Esfahani
Director of
Optometric Services
Dr. David J.
Fuerst
Board Certified
Ophthalmologist
Dr. Nicole
M. Fuerst
Board Certified
Ophthalmologist
Dr. Ramsudha
Narala
Board Certified
Ophthalmologist
page 20

21. Contoso
Pharmaceuticals
EDUCATION:
• Currently there are two program
running at SCEI:
• OPHTHALMICTECHNICIAN
EDUCATION PROGRAM (OTEP)
• GLAUCOMA FELLOWSHIP
PROGRAM
page 21

22. Contoso
Pharmaceuticals
OPHTHALMIC TECHNICIAN EDUCATION PROGRAM (OTEP)
• A team of practitioners working in collaboration
with patients and their families is responsible for
providing high-quality healthcare. As a result of this
dynamic, the Southern California Eye Institute
developed the Ophthalmic Technician Education
Program (OTEP), whose aim is to train highly
qualified allied health professionals dedicated to
meeting the eye care needs of people of all ages.
Ophthalmic technicians perform a variety of tests
and procedures that help ophthalmologists
diagnose and treat eye and vision problems.
• Ophthalmic technicians work closely with patients
and their families to ensure that they recognize
their vision problems and that treatment
procedures are followed. Students in the OTEP
program have the rare opportunity to combine
classroom learning with clinical practice. Consider
becoming an ophthalmic technician if you are
interested in healthcare, enjoy working as part of a
professional team, and want to make a difference
in people's lives. page 22

23. Contoso
Pharmaceuticals
• The Southern California Eye Institute's Ophthalmic Technician Education Program (OTEP) is one of only
14 programs in the country and the only one in California that trains people to become Certified
Ophthalmic Technicians. (For more information on certification through the Joint Commission of Allied
Health Personnel in Ophthalmology (JCAHPO), please click here.) Academic coursework, professional
skills, and clinical training are all integrated into the 21-month OTEP program, which prepares students
for a career as an ophthalmic technician. Students learn the structure and function of the visual system,
master a wide variety of diagnostic tests and procedures, prescribe to and teach patients, and become
valuable members of eye care teams through a series of courses. Clinical rotations at the Southern
California Eye Institute and its associated health centers provide students with supervised real-world
training in eye disease research, diagnosis, and care.
• COVID-19 Updates from the OTEP Program
• The Southern California Eye Institute would like to recognize that we are in the midst of a historic period
that has presented many of us with challenges. The health and safety of our employees and students is
paramount. As a result, we've made adjustments to ensure everyone's safety while also accommodating
schedule and home life changes.
page 23

24. Contoso
Pharmaceuticals
GLAUCOMA FELLOWSHIP PROGRAM
• The clinical and surgical fellowship, which has
been accepted by the Fellowship Compliance
Committee of the Association of University
Professors of Ophthalmology (AUPO), will provide
post-resident trainees with advanced subspecialty
training in glaucoma treatment, diagnosis, and
surgery.
• The program blends university-level education
with clinical hands-on educational experiences,
allowing fellows to obtain in-depth knowledge of
the pathophysiology and treatment of glaucoma
and associated conditions while managing
complex eye disease in a wide range of patients,
from children to adults.
page 24

25. Contoso
Pharmaceuticals
• Traditional surgery, such as glaucoma drain-age devices (Baerveldt/Ahmed), trabeculectomies
(fornix/limbal based), goniotomies, and novel procedures, such as iStent, trabectome, and express shunt,
are all part of the surgical experience.The state-of-the-art imaging and testing facilities at the Southern
California Eye Institute add to the well-rounded experience provided during this crucial year of training.
• "Through the fellowship program, we have the opportunity to train the next generation of glaucoma
leaders and subspecialists in order to better educate and support our community's growing vision needs."
SCEI's Founding Director and Fellowship Director, RohitVarma, MD, MPH, said.
• Fellows have the ability to attend and present at ophthalmology meetings both domestically and
internationally. One fully funded role is open.
page 25

26. Contoso
Pharmaceuticals
REFERENCES:-
• https://sceyes.org/glaucoma-fellowship
• https://sceyes.org/otep
• https://sceyes.org/research
• https://www.hollywoodpresbyterian.com/cha-hollywood-presbyterian-mecial-cener-appoints-rohit-
varma-chief-medical-officer/
• https://www.vitals.com/doctors/Dr_Rohit_Varma.html
• https://health.usnews.com/doctors/rohit-varma-94495
• https://asbarez.com/200325/hollywood-presbyterian-opens-las-first-hospital-based-drive-thru-covid-19-
vaccine-clinic/
• https://pubmed.ncbi.nlm.nih.gov/23493294/
• https://www.businesswire.com/news/home/20181026005485/en/CHA-Hollywood-Presbyterian-Medical-
Center-Announces-Rohit-Varma-MD-MPH-World-Renowned-Eye-Care-Specialist-as-Founding-Director-
of-the-Southern-California-Eyecare-and-Vision-Research-Institute
• https://news.usc.edu/110781/noted-physician-scientist-rohit-varma-named-dean-of-keck-school-of-
medicine-of-usc
page 26

27. Contoso
Pharmaceuticals
ThankYou
Will Watson
+1 23 987 6554
watson@scei.com
www. sceyes.org
page 27